Champions Oncology reported a solid start to FY2025 with Q1 QQ1 2025 revenue of $14.061 million, up 11.9% year over year, supported by ongoing operational improvements and a higher revenue conversion rate. Gross margin expanded to 49.7% (approx. 50%), as cost of sales declined to $7.072 million from $7.5 million a year earlier, underscoring efficiency gains in service delivery. Net income reached $1.313 million with GAAP operating income of $1.329 million and EBITDA of $1.778 million; adjusted EBITDA was $2.0 million, marking a positive earnings trajectory versus prior-year losses. Management characterized the quarter as a continuation of a turnaround that began in the prior year, aided by scalable platforms (PDX bank, in vivo/ex vivo platforms) and a renewed emphasis on cost discipline.